27.07.2011 • News

Pharmaceutical Product Development Q2 Profit Rises

 

Pharmaceutical Product Development reported second-quarter net income attributable to shareholders of $46.51 million or $0.41 per share, compared to $20.98 million or $0.18 per share in the prior-year period.

On average, 12 analysts polled by Thomson Reuters expected earnings of $0.38 per share for the quarter. Analysts' estimate typically excludes one-time items.

Net revenue for the quarter grew 10.2% to $407.70 million from $369.92 million in the second quarter of last year, while11 analysts estimated revenues of $370.79 million for the quarter.

 

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read